Press "Enter" to skip to content

FDA approves new type of therapy to treat advanced urothelial cancer

FDA granted accelerated approval to Padcev, a Nectin-4-directed antibody and microtubule inhibitor conjugate, meaning the drug specifically targets cancer cells – in this case, the cell adhesion molecule Nectin-4 which is highly expressed in urothelial cancers

Original source:

Also Read:   Coronavirus (COVID-19) Update: Daily Roundup June 30, 2020